**Chapter 2**

**Supplemental Data 4: Study characteristics**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First author (year) | Study design | | | N | | Sex M/F | | | Age mean (range) | | Condition for which CS treatment | | Sort of steroid | | Admini-stration | | | Treatment dose mean (range) in mg/day | | | Treatment duration mean (range) in days | |
| Carruthers (1975)72 | Cross-sectionala | | | 13 | | n.r. | | | n.r. | | Psoriasis | | Clobetasol | | Topical | | | (5-300g 0.05%)e | | | (70-549)e | |
| Allenby (1975)17 | RCT/trial | | | 39 | | 20/19 | | | 48 (15-79) | | Psoriasis/atopic  dermatitis/lichen planus | | Clobetasol | | Topical | | | (2.3-38.3g 0.05%)e | | | (6-36)e | |
| Bondarevsky (1976)53 | Cohort | | | 28b | | n.r.c | | | 50 (25-65)d | | Asthma | | Beclomethasone | | Multiplei | | | n.r. | | | (730-7300)e | |
| Wilson KS (1976)85 | Cross-sectional | | | 6 | | n.r. | | | n.r. | | Myeloma | | Prednisolone | | Oral | | | n.r. | | | 854 (549-1220) | |
|  |  | | | 4 | | n.r. | | | n.r. | | Lymphoma | | Prednisolone | | Oral | | | n.r. | | | n.r. | |
| Krupin (1976)54 | Cohort | | | 15 | | n.r. | | | n.r. | | Glaucoma | | Dexamethasone | | Topical | | | 0.25 ml 0,1% | | | 42 | |
| Spiegel (1979)2 | Cohorta | | | 5 | | 4/1 | | | 25.8 (14-59) | | Canceree | | Prednisone | | Oral | | | 56 (40-100) | | | 5.8 (5-8) | |
|  |  | | | 5 | | 3/2 | | | 29.6 (15-49) | | Canceree | | Prednisone | | Oral | | | 56 (40-100) | | | 15.4 (13-20) | |
| Smith (1983)73 | Cross-sectionala | | | 28 | | n.r. | | | 53 (17-76)d | | Asthma | | Beclomethasone | | Inhalation | | | 1 | | | 701 (183-1830) | |
|  |  | | | 11 | | n.r. | | | 53 (17-76)d | | Asthma | | Beclomethasone | | Inhalation | | | 2 | | | 701 (183-1830) | |
| Canafax (1983)55 | Cohort | | | 18 | | 14/4 | | | 27 (11-68) | | Renal transplant | | Prednisone | | Oral | | | 30 (5-90) | | | 610 (15-3690) | |
| Rodger (1986)1 | Cohort | | | 21 | | 12/9 | | | 40 (14-56) | | Renal transplant | | Varioust | | Oral | | | 14.9f | | | 1677 (60-4240) | |
| Ruiz Muñoz (1988)74 | Cross-sectional | | | 21 | | 13/8 | | | 32.8 (14-52) | | Renal transplant | | Prednisolone | | Oral | | | 13.3f | | | (213-275)e | |
| Shapiro (1990)76 | Cross-sectional | | | 13 | | n.r. | | | n.r. | | Renal transplant | | Prednisone | | Oral | | | (5-20)e | | | (21-1830)e | |
| Brown\_1 (1990)75 | Cross-sectional | | | 48 | | 27/11 | | | (16-71)e | | Asthma | | Beclomethasone | | Inhalation | | | (1.5-2.5)e | | | n.r. | |
| Bromberg (1991)56 | Cohort | | | 40 | | n.r. | | | (>17)e | | Renal transplant | | Prednisone | | Oral | | | (5-10)e | | | n.r. | |
| Brown\_2 (1991)77 | Cross-sectional | | | 2 | | n.r.c | | | n.r.c | | Asthma | | Budesonide | | Inhalation | | | 1.2 | | | 305f | |
|  |  | | | 7 | | n.r.c | | | n.r.c | | Asthma | | Budesonide | | Inhalation | | | (1.6-1.8)e | | | 793f | |
|  |  | | | 36 | | n.r.c | | | n.r.c | | Asthma | | Beclomethasone | | Inhalation | | | 1.5 | | | 485f | |
|  |  | | | 26 | | n.r.c | | | n.r.c | | Asthma | | Beclomethasone | | Inhalation | | | 2 | | | 534f | |
|  |  | | | 7 | | n.r.c | | | n.r.c | | Asthma | | Beclomethasone | | Inhalation | | | (2.2-2.65)e | | | 637f | |
| Schlaghecke (1992)10 | Cross-sectionala | | | 279 | | 136/143 | | | 48 (20-83) | | Variouscc | | Variousdd | | Oral | | | (<5->25)e | | | (7-5475)e | |
| Svendsen (1992)18 | RCT/trialu | | | 37 | | n.r. | | | 46.2f | | Asthma | | Budesonide | | Inhalation | | | 1.6 | | | 42 | |
|  |  | | | 37 | | n.r. | | | 46.2f | | Asthma | | Beclomethasone | | Inhalation | | | 1.5 | | | 42 | |
| Hirano (1993)57 | Cohort | | | 8b | | n.r. | | | n.r. | | Renal transplant | | Prednisolone | | Oral | | | 60 | | | (1496-2263)e | |
|  |  | | | 13b | | n.r. | | | n.r. | | Renal transplant | | Prednisolone | | Oral | | | 120 | | | (2080-4855)e | |
| LaRochelle (1993)11 | Cohort | | | 44 | | 11/33 | | | 53.5 (24-87) | | Rheumatic diseases | | Prednisone | | Oral | | | 5.26 (1.5-10) | | | 1403 (91-4758) | |
| Carella (1993)20 | RCT/trial | | | 10 | | 7/3 | | | 28 (20-41) | | Healthy volunteers | | Prednisone | | Oral | | | 70 (10-120) | | | 7 | |
| Brown\_3 (1993)19 | RCT/trial | | | 9b | | n.r.c | | | 43.3f | | Asthma | | Beclomethasone | | Inhalation | | | (1.5-5)e | | | (>28)e | |
|  |  | | | 14b | | n.r.c | | | 46.8f | | Asthma | | Beclomethasone | | Inhalation | | | (1.5-5)e | | | (>28)e | |
| Visscher (1995)21 | RCT/trialu | | | 12 | | 12/0 | | | 23.3 (19-43) | | Healthy volunteers | | Variousq | | Topical | | | 16g 0.1% | | | 5 | |
| Kane (1995)78 | Cross-sectional | | | 22 | | 5/17 | | | 49.8 (25-72) | | Rheumatic diseases | | Prednisolone | | Oral | | | (3-10)e | | | (274-5475)e | |
| Hanania (1995)80 | Cross-sectionala | | | 18 | | 6/12 | | | 36.6f | | Asthma | | Varioush | | Inhalation | | | (>0.8)e | | | (>365)e | |
| Broide (1995)79 | Cross-sectionala | | | 16 | | 10/6 | | | (18-30)e | | Asthma | | Varioush | | Inhalation | | | n.r. | | | (>183)e | |
| Greenberg (1996)23 | RCT/triala | | | 33 | | 10/23 | | | 37 (22-62) | | M. Crohn | | Budesonide | | Oral | | | 3 | | | 91 | |
|  |  | | | 36 | | 18/18 | | | 36 (19-63) | | M. Crohn | | Budesonide | | Oral | | | 6 | | | 91 | |
| Hasegawa (1996)58 | Cohort | | | 11 | | 5/6 | | | 53 (31-73) | | Asthma | | Beclomethasone | | Inhalation | | | (0.8-1.6)e | | | 1468f | |
| Wasserman (1996)22 | RCT/triala | | | 79 | | 50/29 | | | 27 (12-74) | | Asthma | | Fluticasone | | Inhalation | | | 0.1 | | | 94 | |
|  |  | | | 78 | | 47/31 | | | 29 (12-70) | | Asthma | | Fluticasone | | Inhalation | | | 0.2 | | | 94 | |
|  |  | | | 82 | | 58/24 | | | 29 (12-56) | | Asthma | | Fluticasone | | Inhalation | | | 0.5 | | | 94 | |
| Grebe (1997)59 | Cohorta | | | 21 | | 11/10 | | | 53.6f | | Asthma | | Beclomethasone | | Inhalation | | | 1.12f | | | 1752f | |
| Clark (1997)24 | RCT/triala | | | 10 | | 5/5 | | | 28.8f | | Asthma | | Budesonide | | Inhalation | | | 2 | | | n.r. | |
| Kos-Kudla\_1 (1998)81 | Cross-sectionala | | | 22 | | 12/10 | | | 40.4 (21-60) | | Asthma | | Varioush | | Inhalation | | | (0.8-1.6)e | | | n.r. | |
|  |  | | | 36 | | 15/21 | | | 47.7 (21-61) | | Asthma | | Variouso | | Multiplep | | | n.r. | | | 2555 (365-6205) | |
|  |  | | | 19 | | 10/9 | | | 41.9 (22-60) | | Asthma | | Triamcinolone | | Oral | | | (8-20)e | | | n.r. | |
| Wilson AM\_1 (1998)25 | RCT/trialu | | | 16 | | 7/9 | | | 30.7f | | Healthy volunteers | | Triamcinolone | | Nasal | | | 0.055 | | | 4 | |
|  |  | | | 16 | | 7/9 | | | 30.7f | | Healthy volunteers | | Beclomethasone | | Nasal | | | 0.084 | | | 4 | |
|  |  | | | 16 | | 7/9 | | | 30.7f | | Healthy volunteers | | Fluticasone | | Nasal | | | 0.05 | | | 4 | |
| Aaronson (1998)26 | RCT/triala | | | 11b | | n.r.c | | | 35 (21-57)d | | Asthma | | Budesonide | | Inhalation | | | 0.8 | | | 42 | |
|  |  | | | 10b | | n.r.c | | | 29.3 (18-56)d | | Asthma | | Budesonide | | Inhalation | | | 1.6 | | | 42 | |
| (Aaronson (1998)) |  | | | 10b | | n.r.c | | | 27.5 (18-38)d | | Asthma | | Budesonide | | Inhalation | | | 3.2 | | | 42 | |
|  |  | | | 12b | | n.r.c | | | 32.6 (22-52)d | | Asthma | | Prednisone | | Oral | | | 10 | | | 42 | |
| Vargas (1998)27 | RCT/triala | | | 20 | | 18/2 | | | 31.6 (18-56) | | Allergic rhinitis | | Fluticasone | | Inhalation | | | 0.2 | | | 28 | |
|  |  | | | 22b | | n.r.c | | | 34.1 (18-64)d | | Allergic rhinitis | | Fluticasone | | Inhalation | | | 0.8 | | | 28 | |
|  |  | | | 18b | | n.r.c | | | 35.1 (19-65)d | | Allergic rhinitis | | Prednisone | | Oral | | | 7.5 | | | 28 | |
|  |  | | | 21 | | 17/4 | | | 30.7 (18-52) | | Allergic rhinitis | | Prednisone | | Oral | | | 15 | | | 28 | |
| Gazis (1999)28 | RCT/trial | | | 11 | | 8/3 | | | 42.9f | | Nasal polyposis | | Betamethasone | | Nasal | | | 4 drops 0.1% | | | 42 | |
| Franz (1999)29 | RCT/triala | | | 18b | | n.r.c | | | n.r.c | | Psoriasis | | Betamethasone | | Topical | | | 30g 0.1% | | | 7 | |
| Sorkness (1999)30 | RCT/triala | | | 29b | | n.r.c | | | 28.2 (18-50)d | | Asthma | | Fluticasone | | Inhalation | | | 0.5 | | | 28 | |
|  |  | | | 26b | | n.r.c | | | 27.7 (18-49)d | | Asthma | | Fluticasone | | Inhalation | | | 0.1 | | | 28 | |
|  |  | | | 28b | | n.r.c | | | 33 (19-49)d | | Asthma | | Fluticasone | | Inhalation | | | 0.25 | | | 28 | |
|  |  | | | 26b | | n.r.c | | | 29.5 (19-48)d | | Asthma | | Triamcinolone | | Inhalation | | | 0.3 | | | 28 | |
|  |  | | | 26b | | n.r.c | | | 30.7 (18-47)d | | Asthma | | Fluticasone | | Inhalation | | | 0.5 | | | 28 | |
|  |  | | | 26 | | 23/3 | | | 30.9 (19-48) | | Asthma | | Triamcinolone | | Inhalation | | | 0.5 | | | 28 | |
|  |  | | | 26b | | n.r.c | | | 31.4 (19-51)d | | Asthma | | Fluticasone | | Inhalation | | | 0.1 | | | 28 | |
|  |  | | | 27b | | n.r.c | | | 30.2 (19-45)d | | Asthma | | Prednisone | | Oral | | | 10 | | | 28 | |
| Nelson\_1 (1999)31 | RCT/triala | | | 29b | | n.r.c | | | 49 (12-77)d | | Asthma | | Fluticasone | | Inhalation | | | 1 | | | (>112)e | |
|  |  | | | 25b | | n.r.c | | | 50 (15-76)d | | Asthma | | Fluticasone | | Inhalation | | | 2 | | | (>112)e | |
| Li (1999)32 | RCT/triala | | | 21 | | 16/5 | | | 29 (18-42) | | Asthma | | Prednisone | | Oral | | | 10 | | | 28 | |
|  |  | | | 22 | | 15/7 | | | 30 (19-42) | | Asthma | | Fluticasone | | Inhalation | | | 0.44 | | | 28 | |
|  |  | | | 17 | | 14/3 | | | 31 (19-41) | | Asthma | | Fluticasone | | Inhalation | | | 0.176 | | | 28 | |
|  |  | | | 24 | | 14/10 | | | 33 (18-53) | | Asthma | | Triamcinolone | | Inhalation | | | 0.8 | | | 28 | |
|  |  | | | 21 | | 14/7 | | | 34 (23-47) | | Asthma | | Triamcinolone | | Inhalation | | | 0.8 | | | 28 | |
| Wilson AM\_2 (1999)33 | RCT/trial | | | 14 | | 7/7 | | | 33.2f | | Asthma | | Fluticasone | | Inhalation | | | (0.375-1.75)e | | | 15 | |
| Gellner (1999)60 | Cohort | | | 21 | | 7/14 | | | 35 (17-69) | | Variousr | | Variouss | | Oral | | | 5.5 (5-10) | | | 640 (60-4015) | |
| Gupta (2000)34 | RCT/trial | | | 7 | | 1/6 | | | 27 (15-48) | | Asthma | | Beclomethasone | | Inhalation | | | 0.4 | | | 183 | |
|  |  | | | 7 | | 3/4 | | | 31.4 (16-42) | | Asthma | | Beclomethasone | | Inhalation | | | 0.8 | | | 183 | |
| Henzen (2000)61 | Cohort | | | 75 | | 40/35 | | | 65 (18-87) | | Variousv | | Variousw | | Oral | | | (>25)e | | | (5-30)e | |
| Affrime (2000)35 | RCT/triala | | | 16 | | n.r.c | | | n.r.c | | Asthma | | Fluticasone | | Inhalation | | | 1.76 | | | 28 | |
|  |  | | | 16 | | n.r.c | | | n.r.c | | Asthma | | Prednisone | | Oral | | | 10 | | | 28 | |
| (Affrime (2000)) |  | | | 12 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 1.2 | | | 28 | |
|  |  | | | 12 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 0.8 | | | 28 | |
|  |  | | | 16 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 1.6 | | | 28 | |
|  |  | | | 16 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 0.8 | | | 28 | |
|  |  | | | 16 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 1.6 | | | 28 | |
|  |  | | | 16 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 0.8 | | | 28 | |
|  |  | | | 12 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 0.4 | | | 28 | |
|  |  | | | 12 | | n.r.c | | | n.r.c | | Asthma | | Mometasone | | Inhalation | | | 0.4 | | | 28 | |
| Nelson\_2 (2000)36 | RCT/trial | | | 109b | | n.r.c | | | n.r.c | | Asthma | | Triamcinolone | | Inhalation | | | (<3.6)e | | | (>183)e | |
| Patel\_1 (2001)82 | Cross-sectional | | | 22 | | 16/6 | | | 42.1f | | Allergic rhinitis | | Beclomethasone | | Nasal | | | n.r. | | | 311f | |
|  |  | | | 44 | | 22/22 | | | 53.3f | | Allergic rhinitis | | Betamethasone | | Nasal | | | n.r. | | | 421f | |
| Skov (2002)62 | Cohort | | | 25 | | n.r. | | | 18 (9-33)j | | Cystic fibrosis | | Budesonide | | Inhalation | | | (0.8-1.6)e | | | n.r. | |
| Boots (2002)37 | RCT/trial | | | 42b | | n.r.c | | | 55.1d,f | | Renal transplant | | Prednisolone | | Oral | | | 16.6f | | | 91f | |
| Niitsuma (2003)38 | RCT/trialu | | | 12 | | 10/2 | | | 48.2 (32-72) | | Asthma | | Fluticasone | | Inhalation | | | (0.2-0.6)e | | | (84-154)e | |
|  |  | | | 12 | | 10/2 | | | 48.2 (32-72) | | Asthma | | Beclomethasone | | Inhalation | | | (0.2-0.9)e | | | (>84)e | |
| Kos-Kudla\_2 (2003)63 | Cohorta | | | 58 | | 19/39 | | | 48.7f | | Asthma | | Variousl | | Multiplem | | | 0.5 (0.25-0.75)n | | | n.r. | |
| Nguyen (2003)64 | Cohort | | | 13 | | 12/1 | | | 49.9f | | Variousx | | Prednisone | | Oral | | | (10.44-60.44)e | | | 501f | |
|  |  | | | 19 | | 12/7 | | | 51f | | Variousx | | Prednisone | | Oral | | | (10.88-60.88)e | | | 441f | |
|  |  | | | 31 | | 11/20 | | | 45.7f | | Variousx | | Prednisone | | Oral | | | (10-60)e | | | 14 | |
| Patel\_2 (2004)39 | RCT/trial | | | 24 | | 14/10 | | | 41 (16-66)j | | Allergic rhinosinusitis | | Betamethasone | | Nasal | | | 0.2 | | | 56 | |
|  |  | | | 24 | | 13/11 | | | 48 (16-79)j | | Allergic rhinosinusitis | | Mometasone | | Nasal | | | 0.2 | | | 56 | |
| Lee (2004)40 | RCT/trial | | | 10 | | 6/4 | | | 58f | | Asthma | | Fluticasone | | Inhalation | | | 2 | | | (>14)e | |
|  |  | | | 10 | | 2/8 | | | 25f | | Healthy volunteers | | Fluticasone | | Inhalation | | | 2 | | | 14 | |
| Baz-Hecht (2005)65 | Cohort | | | 48 | | 28/20 | | | 43.3 (16-70) | | Kidney/kidney+ pancreas transplant | | Prednisone | | Oral | | | 5f | | | 546f | |
| Bonfils (2006)83 | Cross-sectional | | | 41b | | n.r.c | | | 49.4d,f | | Nasal polyposis | | Prednisolone | | Oral | | | 10.4f | | | 1716f | |
| Kirwan (2006)41 | RCT/triala | | | 37 | | 11/26 | | | 54.2f | | Rheumatoid arthritis | | Budesonide | | Oral | | | 3 | | | 94 | |
| (Kirwan (2006)) |  | | | 35 | | 8/27 | | | 57.8f | | Rheumatoid arthritis | | Budesonide | | Oral | | | 9 | | | 94 | |
|  |  | | | 39 | | 15/24 | | | 53.4f | | Rheumatoid arthritis | | Prednisolone | | Oral | | | 7.5 | | | 94 | |
| Schlessinger (2006)42 | RCT/triala | | | 15b | | n.r.c | | | 14.6 (12-18)d | | Atopic dermatitis | | Fluocinonide | | Topical | | | n.r. | | | 14 | |
|  |  | | | 15b | | n.r.c | | | 14.4 (12-18)d | | Atopic dermatitis | | Fluocinonide | | Topical | | | n.r. | | | 14 | |
| Andres (2006)43 | RCT/trial | | | 14 | | 11/3 | | | 38f | | Psoriasis | | Clobetasol | | Topical | | | n.r. | | | 28 | |
|  |  | | | 12 | | 4/8 | | | 30f | | Psoriasis | | Clobetasol | | Topical | | | n.r. | | | 28 | |
| White (2006)44 | RCT/trial | | | 18 | | 7/11 | | | 51f | | Asthma | | Flunisolide | | Inhalation | | | 1.181f | | | 1250f | |
|  |  | | | 45 | | 17/28 | | | 48f | | Asthma | | Fluticasone | | Inhalation | | | 0.745f | | | 580f | |
|  |  | | | 29 | | 16/13 | | | 47f | | Asthma | | Triamcinolone | | Inhalation | | | 0.448f | | | 1098f | |
|  |  | | | 11 | | 5/6 | | | 60f | | Asthma | | Prednisone | | Oral | | | 26f | | | 305f | |
| Duclos (2007)45 | RCT/trial | | | 10 | | 10/0 | | | 28.8 (17-43) | | Healthy volunteers | | Variousk | | Intra-articular | | | (1.87-7)e | | | 1 | |
| Holme (2008)84 | Cross-sectionala | | | 33 | | 11/22 | | | 64f | | Bronchietasis | | n.r. | | Multiplei | | | n.r. | | | (>365)e | |
| Gonzalez-Moles  (2010)66 | Cohort | | | 62 | | 18/44 | | | 54 (36-79) | | Lichen planus | | Clobetasol | | Topical | | | 10 ml 0.05%  3x5 minf,g | | | (<14-42)e | |
| Fleming (2010)46 | RCT/triala | | | 11b | | n.r.c | | | 45.1 (29-63)d | | Psoriasis | | Betamethasone | | Topical | | | n.r. | | | 28 | |
|  |  | | | 12 | | 6/6 | | | 42.8 (23-58) | | Psoriasis | | Betamethasone | | Topical | | | n.r. | | | 28 | |
|  |  | | | 19 | | 13/6 | | | 48.7 (29-67) | | Psoriasis | | Betamethasone | | Topical | | | n.r. | | | 365 | |
| Neidert (2010)47 | RCT/trial | | | 34b | | 34/0 | | | 32.5 (24.3- 40.8)d | | Healthy volunteers | | Prednisone | | Oral | | | 0.5 mg/kg body  weight | | | 14 | |
| Moghaddam (2012)48 | RCT/trial | | | 31 | | 13/18 | | | 43.1f | | Asthma | | Beclomethasone | | Inhalation | | | 1.5 | | | 21 | |
|  |  | | | 31 | | 12/19 | | | 45.4f | | Asthma | | Fluticasone | | Inhalation | | | 1.5 | | | 21 | |
| Sandhu (2012)67 | Cohort | | | 20 | | 9/11 | | | n.r. | | Variousy | | Variousz | | Topical | | | n.r. | | | 860 (335-2928) | |
| Han (2012)68 | Cohort | | | 103 | | 75/28 | | | 63.5 (33-82) | | Cancerff | | Dexamethasone | | Oral | | | 8f | | | n.r. | |
| Gilchrist (2013)69 | Cohort | | | 12 | | 6/6 | | | 29.8 (18.5-43.5)j | | Cystic fibrosis | | Fluticasone | | Inhalation | | | (0.5-1)e | | | (>365)e | |
|  |  | | | 12 | | 11/1 | | | 25.8 (18.6-44.7)j | | Cystic fibrosis | | Fluticasone | | Inhalation | | | (0.5-1)e | | | (>365)e | |
| Habib\_1 (2013)49 | RCT/triala | | | 19b | | n.r.c | | | 53.3 (43-75)d | | Osteoarthritis | | Betamethasone | | Intra-articular | | | 6 | | | 1 | |
| Kasayama (2013)70 | Cohort | | | 56 | | 17/39 | | | 61f | | Asthma | | Variousaa | | Inhalation | | | 0.502f | | | (>365)e | |
| Silver (2013)50 | RCT/trial | | | 43 | | 33/10 | | | 46.1f | | Psoriasis | | Betamethasone | | Topical | | | 53.5g of 0.5 mg/gf | | | 56 | |
| Jamilloux (2013)8 | Cohort | | | 150 | | 49/101 | | | 74f,j | | Giant cell arteritis | | Prednisone | | Oral | | | (0.7-1mg/kg - 5mg)e | | | (152-2166)e | |
| Sacre (2013)71 | Cohort | | | 60 | | 20/40 | | | 55.8f | | Variousbb | | Prednisone | | Oral | | | 7f | | | 2701 (122-11680) | |
| Habib\_2 (2014)51 | RCT/triala | | | 20 | | 5/15 | | | 60.3f | | Osteoarthritis | | Methylpredni-solone | | Intra-articular | | | 160 | | | 1 | |
| Habib\_3 (2014)52 | RCT/triala | | | 20 | | 12/8 | | | 53.3f | | Osteoarthritis | | Methylpredni-solone | | Intra-articular | | | 80 | | | 1 | |
| n.r.=not reported, CS=corticosteroid, AI=adrenal insufficiency, RCT=randomized controlled trial | | | | | | | | | | | | | |  | | |  | | |  | |  | |
| aonly subgroups with CS use, AI test and of appropriate age included | | | | | | | | | | | | sprednisone, prednisolone, betamethasone and methylprednisolone | | | | | | | | | |  | |
| bnumber of patients tested for AI | | | |  | | |  |  | |  | | tprednisolone and methylprednisolone | | | | |  | | |  | |  | |
| cnot reported for the subgroup of tested patients | | | | | | | |  | |  | | ucross-over design | |  | | |  | | |  | |  | |
| ddata for whole study group, not just tested patients | | | | | | | | | |  | | vchronic obstructive lung disease, cancer chemotherapy, neurological disorders, | | | | | | | | | | | |
| eno mean reported | | |  |  | | |  |  | |  | | inflammatory bowel disease, collagen vascular disorders, anaphylaxis and thyrotoxicosis | | | | | | | | | | | |
| fno range reported | | |  |  | | |  |  | |  | | wprednisone, prednisolone, methylprednisolone and dexamethasone | | | | | | | | | |  | |
| gmouthwash | | |  |  | | |  |  | |  | | xasthma, bronchitis, nasal polyps, urticaria or allergic dermatitis | | | | | | | | | |  | |
| hbeclomethasone and budesonide | | | | |  | |  |  | |  | | ynot specified | |  | | |  | | |  | |  | |
| iinhalation and oral | |  | |  | | |  |  | |  | | zprednisolone, rimexolone and fluorometholone | | | | | | | |  | |  | |
| jmedian instead of mean | | | |  | | |  |  | |  | | aafluticasone, budesonide and beclomethasone | | | | | | | |  | |  | |
| kbetamethasone and cortivazol | | | |  | | |  |  | |  | | bbautoimmune diseases, vasculitis, inflammatory diseases, sarcoidosis and susac syndrome | | | | | | | | | | | |
| ltriamcinolone, betamethasone and fluticasone | | | | | | | |  | |  | | cccollagen vascular disorders, inflammatory bowel disease, chronic obstructive lung | | | | | | | | | | | |
| minhalation, oral and intra-muscular | | | | |  | |  |  | |  | | disease or sarcoidosis | | | |  |  | | |  | |  | |
| ndose only for fluticasone | | | |  | | |  |  | |  | | ddprednisolone, methylprednisolone and fluocortolone | | | | | | | |  | |  | |
| otriamcinolone and beclomethasone | | | | |  | |  |  | |  | | eeleukaemia, lymphoma or Hodgkin's disease | | | | | | |  |  | |  | |
| pintra-muscular and oral | | | |  | | |  |  | |  | | ffvarious carcinomas | |  | | |  | | |  | |  | |
| qhydrocortisone and mometasone | | | |  | | |  |  | |  | |  | |  | | |  | | |  | |  | |
| rchronic inflammatory rheumatic or bowel diseases | | | | | | | |  | |  | |  | |  | | |  | | |  | |  | |